Sodium iodide

Identification

Name
Sodium iodide
Accession Number
DB11119
Description

Sodium iodide is a water-soluble ionic compound with a crystal lattice. Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition 2 but is more commonly used in veterinary medicine. Radiolabelled compound, Iodide I-131, is used as a diagnostic tool to evaluate thyroid function and morphology.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 149.8942
Monoisotopic: 149.89424
Chemical Formula
INa
Synonyms
Not Available

Pharmacology

Indication

Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) 2.

Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

When intravenously administered for total parental nutrition, sodium iodide prevents the depletion of endogenous stores of iodine and subsequent deficiency symptoms 2.

Mechanism of action
Not Available
Absorption

Iodide salts are readily absorbed in the gastrointestinal tract 1.

Volume of distribution

Iodides are distributed widely throughout extracellular fluid of thyroid gland 1.

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Iodides are expected to be renal excreted 1.

Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Acute oral LD50 is 4340 mg/kg in rat and 1000 mg/kg in mouse MSDS. Chronic iodide overdoses may result in iodism, which is commonly characterized by salivation, coryza, sneezing, conjunctivitis, headache, fever, laryngitis, bronchitis, stomatitis, parotitis and oedema of the glottis 1. Up to 10g of sodium iodide has been administered intravenously without any signs of toxicity 1.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Active Moieties
NameKindUNIICASInChI Key
Iodideionic09G4I6V86Q20461-54-5XMBWDFGMSWQBCA-UHFFFAOYSA-M
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Iodopen Sodium IodideInjection, solution118 ug/1mLIntravenousFresenius Kabi USA, LLC2001-07-182015-09-30US flag
Micro ILiquidIntravenousSandoz Canada Incorporated1993-12-31Not applicableCanada flag
Sodium Iodide Inj 100mg/mlLiquidIntravenousSabex Inc1988-12-311999-08-12Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CVS IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalCVS PHARMACY2008-01-01Not applicableUS flag
DDM Iodine Tincture MildSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalDiscount Drug Mart1979-01-01Not applicableUS flag
De La Cruz Tincture of IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalDLC Laboratories, Inc.1979-01-01Not applicableUS flag
GNP Idoinde Tincture 2% MildSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalAmerisource Bergen2008-01-01Not applicableUS flag
Harris Teeter Iodine Tincture MildSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalHarris Teeter1979-01-01Not applicableUS flag
Health Mart Iodine Tincture MildSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalStrategic Sourcing Services LLC2011-01-01Not applicableUS flag
IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalGeiss, Destin, & Dunn2008-11-08Not applicableUS flag
IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalWalgreen Co2011-03-11Not applicableUS flag
IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalSUPERVALU INC.2005-02-04Not applicableUS flag
IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalVi-Jon2017-08-07Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Iodopen Sodium IodideSodium iodide (118 ug/1mL)Injection, solutionIntravenousFresenius Kabi USA, LLC2001-07-182015-09-30US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkali metal iodides. These are inorganic compounds in which the largest halogen atom is Iodine, and the heaviest metal atom is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal salts
Sub Class
Alkali metal iodides
Direct Parent
Alkali metal iodides
Alternative Parents
Inorganic sodium salts
Substituents
Alkali metal iodide / Inorganic salt / Inorganic sodium salt
Molecular Framework
Not Available
External Descriptors
inorganic sodium salt, iodide salt (CHEBI:33167)

Chemical Identifiers

UNII
F5WR8N145C
CAS number
7681-82-5
InChI Key
FVAUCKIRQBBSSJ-UHFFFAOYSA-M
InChI
InChI=1S/HI.Na/h1H;/q;+1/p-1
IUPAC Name
sodium iodide
SMILES
[Na+].[I-]

References

General References
  1. SODIUM IODIDE - National Library of Medicine HSDB Database - Toxnet [Link]
  2. Dailymed - IODOPEN SODIUM IODIDE- sodium iodide injection, solution [Link]
KEGG Compound
C14042
PubChem Compound
5238
PubChem Substance
347827903
ChemSpider
5048
BindingDB
50098561
RxNav
9884
ChEBI
33167
ChEMBL
CHEMBL1644695
Wikipedia
Sodium_iodide
AHFS Codes
  • 40:12.00 — Replacement Preparations
  • 68:36.00 — Thyroid and Antithyroid Agents
MSDS
Download (47.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionTransient Hypothyroxinemia1
2RecruitingTreatmentFallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Clear Cell Tumor / Malignant Ovarian Endometrioid Tumor / Malignant Ovarian Mixed Epithelial Tumor / Malignant Ovarian Serous Tumor / Ovarian Seromucinous Carcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
1Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / Head and Neck Squamous Cell Carcinoma (HNSCC) / HER2/Neu Negative / HER2/Neu Positive / Invasive Breast Carcinoma / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Head and Neck Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Breast Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Triple-Negative Breast Carcinoma1
1Active Not RecruitingTreatmentRecurrent Malignant Mesothelioma / Stage IA Malignant Mesothelioma / Stage IB Malignant Mesothelioma / Stage II Malignant Mesothelioma / Stage III Malignant Mesothelioma / Stage IV Malignant Mesothelioma1
1CompletedTreatmentOvarian Cancer / Primary Peritoneal Cavity Cancer1
1RecruitingTreatmentMetastatic Endometrial carcinoma / Recurrent Endometrial Adenocarcinoma / Recurrent Endometrial Carcinoma / Recurrent Endometrial Clear Cell Adenocarcinoma / Recurrent Endometrial Endometrioid Adenocarcinoma / Recurrent Endometrial Mixed Cell Adenocarcinoma / Recurrent Endometrial Serous Adenocarcinoma / Recurrent Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinosarcoma / Stage IV Uterine Corpus Cancer AJCC v7 / Stage IVA Uterine Corpus Cancer AJCC v7 / Stage IVB Uterine Corpus Cancer AJCC v71
1RecruitingTreatmentMetastatic Malignant Peripheral Nerve Sheath Tumor / Neurofibromatosis Type 1 / Recurrent Malignant Peripheral Nerve Sheath Tumor1
1, 2CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentMalignant Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
Not AvailableCompletedPreventionBacteremia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Solution / dropsTopical
SprayTopical
TinctureTopical
Injection, solutionIntravenous118 ug/1mL
SolutionIntravenous
LiquidIntravenous
TabletOral
LiquidTopical
LiquidIntravenous
Injection, solutionIntravenous37 MBq/mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)651MSDS
boiling point (°C)DecomposesMSDS
water solubilitySolubleMSDS
Predicted Properties
PropertyValueSource
logP1.02ChemAxon
pKa (Strongest Acidic)-9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity13.95 m3·mol-1ChemAxon
Polarizability5.07 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on December 03, 2015 09:51 / Updated on September 25, 2020 15:13

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates